These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30772201)

  • 1. Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.
    Takahashi K
    J Clin Neurosci; 2019 May; 63():91-94. PubMed ID: 30772201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis.
    Fragoso YD; Alves-Leon SV; Becker J; Brooks JB; Correa EC; Damasceno A; Gama PD; Gama RA; Matta AP; Maciel EP; Winckler TC
    Arq Neuropsiquiatr; 2016 Aug; 74(8):650-2. PubMed ID: 27556377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased?
    Nakahara J; Tomaske L; Kume K; Takata T; Kamada M; Deguchi K; Kufukihara K; Schneider R; Gold R; Ayzenberg I
    Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e559. PubMed ID: 31044147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
    Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
    CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
    Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
    PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
    Warnke C; Olsson T; Hartung HP
    Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte recovery after fingolimod discontinuation in patients with MS.
    Nagy S; Kuhle J; Derfuss T
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
    Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
    Ghadiri M; Fitz-Gerald L; Rezk A; Li R; Nyirenda M; Haegert D; Giacomini PS; Bar-Or A; Antel J
    Mult Scler; 2017 Aug; 23(9):1225-1232. PubMed ID: 28749311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS.
    Fox EJ; Lublin FD; Wolinsky JS; Cohen JA; Williams IM; Meng X; Ziehn M; Kolodny S; Cree BAC
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31511330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod.
    Watanabe M; Nakamura Y; Isobe N; Tanaka M; Sakoda A; Hayashi F; Kawano Y; Yamasaki R; Matsushita T; Kira JI
    J Neuroinflammation; 2020 Jul; 17(1):206. PubMed ID: 32646493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebral toxoplasmosis in an MS patient receiving Fingolimod.
    Enriquez-Marulanda A; Valderrama-Chaparro J; Parrado L; Diego Vélez J; Maria Granados A; Luis Orozco J; Quiñones J
    Mult Scler Relat Disord; 2017 Nov; 18():106-108. PubMed ID: 29141790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data.
    Sinnecker T; Hadisurya J; Schneider-Hohendorf T; Schwab N; Wrede K; Gembruch O; Gold R; Hellwig K; Pilgram-Pastor S; Adams O; Albrecht P; Hartung HP; Aktas O; Kraemer M
    BMC Neurol; 2019 Aug; 19(1):190. PubMed ID: 31399069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
    Harrer A; Wipfler P; Pilz G; Oppermann K; Haschke-Becher E; Afazel S; Kraus J; Trinka E; Sellner J
    Int J Mol Sci; 2015 Sep; 16(9):21832-45. PubMed ID: 26378517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
    Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
    J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
    Sato K; Niino M; Kawashima A; Yamada M; Miyazaki Y; Fukazawa T
    Intern Med; 2018 Sep; 57(18):2647-2655. PubMed ID: 29709955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis.
    Ladrón Abia P; Alcalá Vicente C; Martínez Delgado S; Bastida Paz G
    Gastroenterol Hepatol; 2021 Feb; 44(2):156-157. PubMed ID: 33199131
    [No Abstract]   [Full Text] [Related]  

  • 18. Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.
    Evangelopoulos ME; Koutoulidis V; Andreadou E; Evangelopoulos DS; Kilidireas C
    Int J Neurosci; 2016 Dec; 126(12):1097-102. PubMed ID: 26727713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
    Fragoso YD
    Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fingolimod-associated PML in a patient with prior immunosuppression.
    Gyang TV; Hamel J; Goodman AD; Gross RA; Samkoff L
    Neurology; 2016 May; 86(19):1843-5. PubMed ID: 27164718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.